Pharma BD Deal Intelligence

Sumitomo Dainippon Pharma Co., Ltd. / Roivant Sciences Ltd. (Sumitovant five-Vant deal)

2019 · Asset Purchase · $3.0B · Complete

A validating exit for Roivant's holding-company model: Sumitomo paid roughly $3 billion for five Vant subsidiaries plus a stake in Roivant itself, ahead of Sumitomo's Latuda loss of exclusivity, though Urovant was taken private again within a year.

Outcome grade pending — assessed 5 years post-close.

Full analysis, sources & comparables →

The coverage arc

Sep 06, 2019 BioSpace Bullish

Ramaswamy: 'They have great cash flow but no meaningful growth engine. We have a great growth engine and no meaningful cash flows' — analysts read this as a…

Dec 28, 2019 Sumitomo Dainippon Pharma (IR) Neutral

Completion of the strategic alliance with Roivant Sciences, effective December 27, 2019: ~US$3B (JPY 330B) = US$2.0B for all stock of Sumitovant Biopharma +…

Mar 10, 2023 PRNewswire (Sumitovant Biopharma) Neutral

Sumitovant completed acquisition of Myovant Sciences on March 10, 2023 (~$1.7B for shares not already owned); Myovant delisted from the NYSE.

Source summaries from our enrichment pipeline; follow links for originals.

All 8 sources with sentiment breakdown →

Sumitomo Dainippon Pharma acquired Roivant's interests in five 'Vant' subsidiaries — Myovant, Urovant, Enzyvant, Altavant and Spirovant — bundled under a new holding company, Sumitovant Biopharma, plus an equity stake in Roivant itself. Per Sumitomo's completion disclosure, total consideration was approximately US$3 billion (~JPY 330 billion): US$2.0 billion for 100% of Sumitovant Biopharma (the five Vants) and US$1.0 billion for an 11% equity stake in Roivant. The deal also granted Sumitomo options over six additional Roivant biopharma companies and access to Roivant's DrugOme and Digital Innovation technology platforms. Announced October 31, 2019; closed December 27, 2019, with Sumitovant launched as a wholly owned subsidiary led by CEO Myrtle Potter. Sumitomo subsequently consolidated the portfolio: Urovant was taken private (announced November 2020); Sumitovant completed the buy-in of the remaining Myovant shares it did not own on March 10, 2023 (~US$1.7 billion, NYSE delisting); and the U.S. entities were combined into Sumitomo Pharma America effective July 1, 2023.

Did it work? Outcome assessment

Strategic verdict
Failed to Achieve
Financial impact
Impaired/Written Down
By FY2023 (year to March 2024) Sumitomo Pharma reported an operating loss of ~JPY354.9B (vs ~JPY77B prior), revenue down ~43%. Charges included a ~JPY133.5B impairment on MYFEMBREE (relugolix) patent rights, ~JPY35.9B goodwill impairment in the North America business, ~JPY10.6B IPR&D impairments on discontinued compounds, and ~JPY8.7B restructuring at a US subsidiary.
Pipeline outcome
Mixed
Vant assets reached market (relugolix as Orgovyx/Myfembree via Myovant, Gemtesa via Urovant, plus Enzyvant approvals), so assets advanced. But commercial uptake fell far short of forecasts; Sumitomo fully acquired/took Myovant private in 2023 and consolidated the Vants, then impaired Myfembree and North America goodwill as the post-Latuda revenue base failed to compensate for the lurasidone patent cliff.

Key facts

Disease & market context

Multiple (uterine fibroids, advanced prostate cancer, overactive bladder, rare pediatric/respiratory disease)

Disease Overview

Sumitovant's portfolio spans high-prevalence women's/men's health (uterine fibroids, endometriosis, advanced prostate cancer, overactive bladder) and ultra-rare pediatric immune, pulmonary hypertension, and cystic fibrosis indications. The lead Vants (Myovant, Urovant) targeted GnRH/beta-3 mechanisms with Phase 3 readouts already in hand at the time of deal close.

Competitive Landscape

The Sumitovant alliance is best understood as a portfolio bet, not a single-indication play. Myovant's relugolix (oral GnRH antagonist) was advancing Phase 3 in uterine fibroids (LIBERTY) and advanced prostate cancer (HERO) against AbbVie/Neurocrine's Orilissa (elagolix, endometriosis) and entrenched leuprolide depot brands (Lupron, Eligard, Trelstar). Urovant's vibegron (beta-3 agonist) had positive Phase 3 EMPOWUR data in overactive bladder, positioning it against Astellas' Myrbetriq plus generic antimuscarinics. Enzyvant carried RVT-802 for congenital athymia (later approved as Rethymic, 2021), Altavant held rodatristat ethyl for pulmonary arterial hypertension (vs. United Therapeutics' tyvaso/Uptravi franchise), and Spirovant pursued AAV gene therapy for cystic fibrosis (vs. Vertex's Trikafta dominance). For Sumitomo Dainippon, the deal was a pre-Latuda-LOE diversification play to replace the schizophrenia revenue cliff in 2023; for Roivant, it monetized late-stage assets while preserving optionality on six additional Vants. Analysts framed the price as full but defensible given relugolix/vibegron Phase 3 reads, and Stifel/Jefferies modeled blockbuster potential for the lead programs.

Related deals — scored

DealYearValueOutcome
Sumitomo Dainippon Pharma Co., Ltd. / Roivant Sciences Ltd. (Sumitovant five-Vant deal) (this deal)2019$3.0B
Sumitomo Dainippon Pharma Co., Ltd. / Cynapsus Therapeutics Inc.2016$624M28
Sumitomo Dainippon Pharma Co., Ltd. / Tolero Pharmaceuticals, Inc.2016$780M24
Sumitomo Dainippon Pharma Co., Ltd. / Otsuka Pharmaceutical Co., Ltd.2021$270M
AstraZeneca PLC / Daiichi Sankyo Company, Limited2019$6.9B100
Novartis AG / Endocyte, Inc.2018$2.1B96
Astellas Pharma Inc. / Seagen Inc.2009$4.5B95

Compare all 7 side-by-side →

See the full interactive analysis, sources & comparables →